Literature DB >> 16491832

Non-Hodgkin's lymphoma manifest as gingival hyperplasia in a renal transplant recipient.

Jung Hyun Kwon1, Joon Chang Song, Sang Hun Lee, So Young Lee, Chul Woo Yang, Yong Soo Kim, Byung Kee Bang.   

Abstract

Gingival hyperplasia is a frequent complication in transplant patients who receive cyclosporine or calcium channel blockers. We studied an unusual case involving a renal transplant recipient with post-transplant non-Hodgkin's lymphoma that manifested as gingival hyperplasia. We initially consider that it was a side effect of cyclosporine and nifedipine. The lesion did not respond to dose reductions or the withdrawal of cyclosporine and nifedipine, and the gingival hyperplasia progressed in a localized fashion, becoming ulcerated and bleeding easily. Histological examination revealed the presence of malignant lymphoma.

Entities:  

Mesh:

Year:  2005        PMID: 16491832      PMCID: PMC3891080          DOI: 10.3904/kjim.2005.20.4.330

Source DB:  PubMed          Journal:  Korean J Intern Med        ISSN: 1226-3303            Impact factor:   2.884


  27 in total

1.  Posttransplantation lymphoproliferative disorder: case report.

Authors:  A Perkowska; M Durlik; W Suleiman; R Maryniak; Z Gaciong; J Juskowa; Z Rostamzadeh Khameneh; J Szmidt; M Lao
Journal:  Transplant Proc       Date:  2000-09       Impact factor: 1.066

2.  Cyclosporin, nifedipine and gingival hyperplasia: a randomized controlled study.

Authors:  J D Morgan; M J Swarbrick; C M Edwards; P K Donnelly
Journal:  Transpl Int       Date:  1994       Impact factor: 3.782

3.  Risk factors in the development of cyclosporine-induced gingival overgrowth.

Authors:  D W Thomas; R G Newcombe; G R Osborne
Journal:  Transplantation       Date:  2000-02-27       Impact factor: 4.939

4.  Medication influencing the development of gingival overgrowth in renal transplant patients.

Authors:  E Varga; L H Mair
Journal:  Transplant Proc       Date:  1998-08       Impact factor: 1.066

Review 5.  Risk factors for drug-induced gingival overgrowth.

Authors:  R A Seymour; J S Ellis; J M Thomason
Journal:  J Clin Periodontol       Date:  2000-04       Impact factor: 8.728

6.  Preventing acute rejection, Epstein-Barr virus infection, and posttransplant lymphoproliferative disorders after kidney transplantation: use of aciclovir and mycophenolate mofetil in a steroid-free immunosuppressive protocol.

Authors:  S A Birkeland; H K Andersen; S J Hamilton-Dutoit
Journal:  Transplantation       Date:  1999-05-15       Impact factor: 4.939

7.  Posttransplant lymphoproliferative disorders in renal allograft recipients: report of 53 cases of a French multicenter study. PTLD French Working Group.

Authors:  S Caillard; V Lachat; B Moulin
Journal:  Transpl Int       Date:  2000       Impact factor: 3.782

8.  [Lymphoproliferative syndromes after renal transplantation].

Authors:  Y Le Meur; N Potelune; A Jaccard; B Petit; D Bordessoule; P Peyronnet; S Ranger; F Labrousse; C Leroux-Robert
Journal:  Nephrologie       Date:  1998

9.  Mycophenolate, tacrolimus and post-transplant lymphoproliferative disorder: a report of the North American Pediatric Renal Transplant Cooperative Study.

Authors:  Vikas R Dharnidharka; Ping-Leung Ho; Donald M Stablein; William E Harmon; Amir H Tejani
Journal:  Pediatr Transplant       Date:  2002-10

Review 10.  Drug-induced gingival hyperplasia in transplant recipients.

Authors:  Kerri A Hood
Journal:  Prog Transplant       Date:  2002-03       Impact factor: 1.065

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.